Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)

Key Inclusion Criteria:

   - Participants with Myelodysplastic Syndrome (MDS) defined according to World Health
   Organization classification, with Revised International Prognostic Scoring System
   (IPSS-R) prognostic risk category of intermediate, high, or very high risk.

   - Adequate performance status and hematological, liver, and kidney function

Key Exclusion Criteria:

   - Immediate eligibility for allogenic stem cell transplant (SCT), as determined by the
   investigator, with an available donor

   - Prior treatment with Cluster of Differentiation (CD) 47 or Signal-regulatory protein
   alpha (SIRPα)-targeting agents

   - Any prior antileukemic therapy for treatment of intermediate, high, very high risk MDS
   per IPSS-R

   - Second malignancy, except treated basal cell or localized squamous skin carcinomas,
   localized prostate cancer, or other malignancies for which participants are not on
   active anticancer therapies and have had no evidence of active malignancy for at least
   ≥ 1 year

   - Contraindications to azacitidine

   - Clinical suspicion of active central nervous system (CNS) involvement by MDS

   - Known active or chronic hepatitis B or C infection or human immunodeficiency virus in
   medical history

   - Active hepatitis B virus and/or active hepatitis C virus, and/or HIV following testing
   at screening

   - Pregnancy or active breastfeeding

Note: Other protocol defined Inclusion/Exclusion criteria may apply.